BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition